クローニングおよび突然変異誘発の市場規模、シェア、動向分析レポート：製品別（クローニングキット、変異誘発キット）、技術別（Topo PCRクローニング、Blunt Endクローニング）、最終用途別、地域別、セグメント予測、2023年～2030年

クローニングおよび突然変異誘発の市場成長・動向

Grand View Research, Inc.の新しいレポートによると、世界のクローニングおよび突然変異誘発の市場規模は、2023年から2030年までCAGR18.97%で拡大し、2030年には94億4000万米ドルに達すると予測されています。医薬品開発のためのタンパク質工学への注目の高まりと、遺伝子組み換え製品への需要の増加が、市場を牽引する主な要因となっています。また、遺伝性疾患や慢性疾患の増加により、個別化医療に対する需要が高まっています。

クローニングおよび突然変異誘発は、医薬品開発におけるタンパク質工学で採用されている基本的な手法です。これらの技術は、治療用タンパク質を開発するために、ヌクレオチドの挿入、欠失、置換によってタンパク質配列を変更する際に研究者を支援します。さらに、クローニングおよび突然変異誘発は、より効率的で安全な医薬品の開発を助け、より低いコストで容易に入手することができます。例えば、現在FDAが承認しているペプチドやタンパク質の医薬品は200種類以上あります。したがって、これらの技術をタンパク質工学に応用することで、予測期間中に市場の成長が促進される可能性があります。

COVID-19のパンデミックは、市場成長にプラスの影響を与えると予想されます。SARS-CoV-2ゲノムのクローニングには、クローニングおよび突然変異誘発の技術が使用されています。例えば、2020年5月にNatureに掲載された論文によると、研究者は酵母ベースの方法を用いてSARC-CoV-2ゲノムのクローンを構築しています。ゲノムの改変や再構築は、感染や複製の方法、ウイルスに効く可能性のある薬剤やワクチンの研究に不可欠です。その結果、COVID-19関連の研究によりこれらの技術の利用が増加し、予測期間中の市場成長を促進することが期待されます。

遺伝性疾患や慢性疾患の有病率の増加により、個別化医療の需要が高まっています。クローニングおよび突然変異誘発技術は、診断を助け、治療計画を立て、治療効果を確認するために、個人の特定の疾患を研究する際に使用されます。さらに、個別化医療のための資金調達の増加は、研究期間中にクローニングおよび突然変異誘発のアプリケーションを後押しすると予想されます。例えば、2022年2月、VariantyxSは、精密腫瘍学の新規ソリューションを発売するために4150万米ドル相当の資金を確保しました。

さらに、合成生物学におけるクローニングおよび突然変異誘発ツールの用途の増加が、市場の成長を加速しています。合成生物学は、クローニングおよび突然変異誘発を利用して、すでに利用可能な薬剤の治療特性を改善し、個人に対する副作用を最小限またはゼロにすることで、薬剤の微調整に役立っています。合成遺伝子は、患者の腫瘍の特定のDNA配列に合わせた個別化がんワクチンを開発する道を、腫瘍学に特化した組織に開きました。このような個別化がんワクチンのいくつかは、臨床段階にあります。COVID-19と戦うために開発中の遺伝子ベースのワクチンもいくつかありますが、費用対効果が高く効率的なワクチンを製造するには、クローニングおよび突然変異誘発の技術が必要です。このような用途は、調査期間中の市場成長を促進すると予想されます。

一方、クローニングおよび突然変異誘発生成ツールに関連する高い維持費、資格を有する研究者の生存能力の制限、および高度なトレーニングの必要性が、ある程度まで市場成長を制限する可能性があります。しかし、主なプレイヤーは、費用対効果の高い機器を開発するために継続的に努力しており、制限を克服するためにいくつかのハンズオントレーニングプログラムを提供しており、これは市場の成長の見通しを作成する可能性があります。

クローニングおよび突然変異誘発の市場レポートハイライト

製品別では、クローニングキットセグメントが2022年に最大のシェアを占めました。これは、バイオ医薬品、遺伝子治療、遺伝子解析など、これらのキットの幅広い用途に起因するものである

技術別では、TOPO PCRクローニングセグメントが2022年に最大シェアを占めました。これは、ライゲーションや制限のないクローニング、プライマーの簡単な設計といった技術に関連する利点によるものです。

最終用途別では、バイオ医薬品や製薬会社が、創薬や薬剤開発のためにクローニングおよび突然変異誘発が広く使用されていることから、2022年に最大のシェアを占めました。

政府による投資イニシアチブの増加、がんなどの慢性疾患の発生率の増加、バイオテクノロジー技術への高い需要により、2022年には北米が世界市場を独占

アジア太平洋地域は、政府による研究開発投資の増加、新規治療薬に対する需要の高まり、経済の改善により、将来的に大幅な成長が見込まれています。

目次

第1章 調査手法

• 市場セグメンテーションと範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国別の市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報一覧
• 一次情報のリスト
• 目的
• 略語一覧

第2章 市場の定義

第3章 エグゼクティブサマリー

• 市場概要

第4章 世界のクローニングおよび突然変異誘発市場の変数、動向、および範囲

• クローニングおよび突然変異誘発市場系統の見通し
  • 親市場の見通し
• 浸透と成長の見通しのマッピング
• 規制の枠組み
• 市場促進要因分析
  • 個別化医療の需要の高まり
  • タンパク質工学への関心の高まり
  • 遺伝子組み換え製品の需要の高まり
• 市場抑制要因分析
  • クローニングおよび突然変異誘発のツールと機器に関連する高額なメンテナンスコスト
  • 資格のある研究者の限られた利用可能性と、クローニングおよび突然変異誘発プロセスに関する高度なトレーニングの必要性
• 市場機会分析
  • 合成生物学におけるクローニングおよび突然変異誘発の応用の増加
• ポーターのファイブフォース分析
• クローニングおよび突然変異誘発市場： COVID-19の影響分析

第5章 クローニングおよび突然変異誘発市場：セグメント分析、製品別、2018年から2030年（100万米ドル）

• 世界のクローニングおよび突然変異誘発市場：製品変動分析
• クローニングキット
• 突然変異誘発キット
• その他

第6章 クローニングおよび突然変異誘発市場：セグメント分析、テクノロジー別、2018年～2030年（100万米ドル）

• 世界のクローニングおよび突然変異誘発市場：技術変動分析
• トポPCRクローニング
• 平滑末端クローニング
• シームレスなクローニング
• 部位特異的突然変異誘発
• その他

第7章 クローニングおよび突然変異誘発市場：セグメント分析、最終用途別、2018年～2030年（100万米ドル）

• クローニングおよび突然変異誘発市場：エンドユーザーの変動分析
• バイオ医薬品および製薬会社
• CROとCMO
• 学術・調査機関

第8章 クローニングおよび突然変異誘発市場：-セグメント分析、地域別、2018年～2030年（100万米ドル）

• クローニングおよび突然変異誘発市場：地域変動分析
• 北米
  • SWOT分析
  • 米国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • カナダ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 欧州
  • SWOT分析
  • ドイツ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 英国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • フランス
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • イタリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スペイン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • デンマーク
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スウェーデン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • ノルウェー
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• アジア太平洋地域
  • SWOT分析
  • 日本
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 中国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • インド
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 韓国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • オーストラリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • タイ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• ラテンアメリカ
  • SWOT分析
  • ブラジル
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • メキシコ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アルゼンチン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• MEA
  • SWOT分析
  • 南アフリカ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • サウジアラビア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • クウェート
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ

第9章 競合情勢

• 参加者の概要
  • アジレント・テクノロジーズ株式会社
  • タカラバイオ株式会社
  • サーモフィッシャーサイエンティフィック社
  • ニューイングランドバイオラボ
  • メルクKGaA
  • プロメガ株式会社
  • バイオ・ラッドラボラトリーズ株式会社
  • ダナハー
  • イエナバイオサイエンス GmbH
  • アッセイジェニー
  • 株式会社トランスジェンバイオテック
• 財務実績
• 参入企業
  • 市場のリーダー
    • クローニングおよび突然変異誘発の市場シェア分析、2022年
  • 戦略マッピング
    • 拡張
    • 取得
    • コラボレーション
    • 製品・サービスのローンチ
    • パートナーシップ
    • その他

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. Global Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 4. Global Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 5. Global Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 6. Global Cloning and Mutagenesis Market, by Region, 2018 - 2030 (USD Million)
• Table 7. North America Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
• Table 8. North America Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 9. North AmericaCloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 10. North America Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 11. U.S. Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 12. U.S. Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 13. U.S. Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 14. Canada Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 15. Canada Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 16. Canada Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 17. Europe Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
• Table 18. Europe Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 19. EuropeCloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 20. Europe Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 21. U.K. Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 22. U.K. Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 23. U.K. Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 24. Germany Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 25. Germany Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 26. Germany Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 27. France Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 28. France Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 29. France Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 30. Italy Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 31. Italy Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 32. Italy Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 33. Spain Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 34. Spain Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 35. Spain Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 36. Denmark Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 37. Denmark Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 38. Denmark Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 39. Sweden Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 40. Sweden Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 41. Sweden Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 42. Norway Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 43. Norway Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 44. Norway Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 45. Asia Pacific Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
• Table 46. Asia Pacific Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 47. Asia Pacific Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 48. Asia Pacific Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 49. China Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 50. China Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 51. China Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 52. India Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 53. India Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 54. India Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 55. Japan Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 56. Japan Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 57. Japan Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 58. Thailand Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 59. Thailand Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 60. Thailand Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 61. Australia Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 62. Australia Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 63. Australia Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 64. South Korea Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 65. South Korea Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 66. South Korea Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 67. Latin America Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
• Table 68. Latin America Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 69. Latin America Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 70. Latin America Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 71. Brazil Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 72. Brazil Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 73. Brazil Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 74. Mexico Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 75. Mexico Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 76. Mexico Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 77. Argentina Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 78. Argentina Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 79. Argentina Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 80. Middle East & Africa Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
• Table 81. Middle East & Africa Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 82. Middle East & Africa Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 83. Middle East & Africa Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 84. South Africa Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 85. South Africa Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 86. South Africa Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 87. Saudi Arabia Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 88. Saudi Arabia Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 90. UAE Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 91. UAE Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 92. UAE Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
• Table 93. Kuwait Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
• Table 94. Kuwait Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
• Table 95. Kuwait Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million) 

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Cloning and Mutagenesis, Market Segmentation
• Fig. 8 Market Snapshot, 2022
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
• Fig. 16 Global Cloning and Mutagenesis Market: Product Movement Analysis
• Fig. 17 Global Cloning and Mutagenesis Market, for Cloning Kits, 2018 - 2030 (USD Million)
• Fig. 18 Global Cloning and Mutagenesis Market, for Mutagenesis Kits, 2018 - 2030 (USD Million)
• Fig. 19 Global Cloning and Mutagenesis Market, for Others, 2018 - 2030 (USD Million)
• Fig. 20 Global Cloning and Mutagenesis Market: Technology Movement Analysis
• Fig. 21 Global Cloning and Mutagenesis Market, for Topo PCR Cloning, 2018 - 2030 (USD Million)
• Fig. 22 Global Cloning and Mutagenesis Market, for Blunt End Cloning, 2018 - 2030 (USD Million)
• Fig. 23 Global Cloning and Mutagenesis Market, for Seamless Cloning, 2018 - 2030 (USD Million)
• Fig. 24 Global Cloning and Mutagenesis Market, for Site-Directed Mutagenesis, 2018 - 2030 (USD Million)
• Fig. 25 Global Cloning and Mutagenesis Market, for Others, 2018 - 2030 (USD Million)
• Fig. 26 Global Cloning and Mutagenesis Market: End-user Movement Analysis
• Fig. 27 Global Cloning and Mutagenesis Market, for Biopharmaceutical & Pharmaceutical Companies, 2018 - 2030 (USD Million)
• Fig. 28 Global Cloning and Mutagenesis Market, for CROs & CMOs, 2018 - 2030 (USD Million)
• Fig. 29 Global Cloning and Mutagenesis Market, for Academic & Research Institutes, 2018 - 2030 (USD Million)
• Fig. 30 Regional Marketplace: Key Takeaways
• Fig. 31 Regional Outlook, 2022 & 2030
• Fig. 32 Global Cloning and Mutagenesis Market: Regional Movement Analysis
• Fig. 33 North America Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 34 U.S. Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 35 Canada Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 36 Europe Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 37 U.K. Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 38 Germany Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 39 France Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 40 Italy Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 41 Spain Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 42 Denmark Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 43 Sweden Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 44 Norway Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 45 Asia Pacific Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 46 China Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 47 India Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 48 Japan Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 49 South Korea Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 50 Australia Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 51 Thailand Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 52 Latin America Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 53 Brazil Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 54 Mexico Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 55 Argentina Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 56 Middle East and Africa Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 57 South Africa Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 59 UAE Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
• Fig. 60 Kuwait Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)

Cloning And Mutagenesis Market Growth & Trends:

The global cloning and mutagenesis market size is expected to reach USD 9.44 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 18.97% from 2023 to 2030. Growing focus on protein engineering for drug development and increasing demand for genetically modified products are major factors driving the market. In addition, the rising prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine.

Cloning and mutagenesis are the basic methodologies employed in protein engineering during drug development. These techniques help researchers in the modification of protein sequences through insertion, deletion, or substitution of nucleotides to develop therapeutic proteins. In addition, cloning and mutagenesis aid in the development of more efficient and safer drugs, which can be readily available at a lower cost. For instance, currently, there are more than 200 peptide and protein drugs approved by the FDA. Hence, applications of these techniques in protein engineering are likely to fuel market growth over the forecast years.

The COVID-19 pandemic is expected to positively influence market growth. Cloning and mutagenesis techniques are used to clone the SARS-CoV-2 genome. For instance, according to an article published in Nature in May 2020, researchers have constructed a clone of the SARC-CoV-2 genome by using yeast-based method. Modifying or reconstructing genomes is essential for studying methods of infection, replication, and potential drugs and vaccines that might work against the virus. As a result, the usage of these techniques has increased due to COVID-19-related research, which is expected to fuel the market growth during the forecast period.

The growing prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine. Cloning and mutagenesis techniques are used in studying a particular disease of an individual to aid diagnosis, develop a treatment plan, and identify the treatment effect. Moreover, increasing funding for personalized medicine is anticipated to boost the applications of cloning and mutagenesis during the study period. For instance, in February 2022, VariantyxS secured funding worth USD 41.5 million to launch novel solutions in precision oncology.

Furthermore, increasing applications of cloning and mutagenesis tools in synthetic biology are accelerating market growth. Synthetic biology is aiding in fine-tuning of already available drugs by using cloning and mutagenesis to improve their therapeutic attributes and produce minimal or no side effects for individuals. Synthetic genes created the way for oncology-focused organizations to develop personalized cancer vaccines to the specific DNA sequence of a patient's tumor. Several such personalized cancer vaccines are in the clinical phase. There are several gene-based vaccines that are also in development to fight COVID-19, which require cloning and mutagenesis techniques to produce cost-effective and efficient vaccines. Such applications are expected to fuel the market growth during the study period.

On the other hand, high maintenance cost associated with cloning and mutagenesis tools, limited viability of qualified researchers. and the need for advanced training may limit the market growth to a certain extent. However, key players are continuously striving to develop cost-effective instruments and offering several hands-on training programs to overcome the limitations, which is likely to create growth prospects for the market.

Cloning And Mutagenesis Market Report Highlights:

• By product, the cloning kits segment held the largest share in 2022. This is attributed to the broad range of applications of these kits in biopharmaceuticals, gene therapy, and gene analysis among others

• By technology, the TOPO PCR cloning segment held the largest share in 2022 due to the advantages associated with the technology such as ligation and restriction-free cloning and simple design of primers

• By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cloning and mutagenesis in biopharmaceuticals for drug discovery and development

• North America dominated the global market in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and high demand for biotechnology techniques

• Asia Pacific is expected to grow considerably in the future owing to the increasing R&D investment by governments, rising demand for novel therapeutics, and improving economy

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
    • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
• 1.7 Global Market: CAGR Calculation
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1:
  • 1.11.2 Objective 2:
• 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

• 3.1 Market Summary

Chapter 4 Global Cloning and Mutagenesis Market Variables, Trends, & Scope

• 4.1 Cloning and Mutagenesis Market Lineage Outlook
  • 4.1.1 Parent market outlook
• 4.2 Penetration and Growth Prospect Mapping
• 4.3 Regulatory Framework
• 4.4 Market Driver Analysis
  • 4.4.1 Increasing demand for personalized medicine
  • 4.4.2 Growing focus on protein engineering
  • 4.4.3 Rising demand for genetically modified products
• 4.5 Market Restraint Analysis
  • 4.5.1 High maintanance cost associated with cloning and mutagenesis tools & instruments
  • 4.5.2 Limited aviability of qualified researchers and need for advanced training in cloning and mutagenesis processes
• 4.6 Market Opportunity Analysis
  • 4.6.1 Increasing applications of cloning and mutagenesis in synthetic biology
• 4.7 Porter's Five Forces Analysis
• 4.8 Cloning and Mutagenesis Market: Covid-19 Impact Analysis

Chapter 5 Cloning and Mutagenesis Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

• 5.1 Global Cloning and Mutagenesis Market: Product Movement Analysis
• 5.2 Cloning Kits
  • 5.2.1 Cloning kits market estimates and forecast, 2018 - 2030 (USD Million)
• 5.3 Mutagenesis Kits
  • 5.3.1 Mutagenesis kits market estimates and forecast, 2018 - 2030 (USD Million)
• 5.4 Others
  • 5.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cloning and Mutagenesis Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)

• 6.1 Global Cloning and Mutagenesis Market: Technology Movement Analysis
• 6.2 Topo PCR Cloning
  • 6.2.1 Topo PCR cloning market estimates and forecast, 2018 - 2030 (USD Million)
• 6.3 Blunt End Cloning
  • 6.3.1Blunt end cloning market estimates and forecast, 2018 - 2030 (USD Million)
• 6.4 Seamless Cloning
  • 6.4.1 Seamless cloning market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5 Site-Directed Mutagenesis
  • 6.5.1 Site-directed mutagenesis market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6 Others
  • 6.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cloning and Mutagenesis Market - Segment Analysis, by End-user, 2018 - 2030 (USD Million)

• 7.1 Cloning and Mutagenesis Market: End-user Movement Analysis
• 7.2 Biopharmaceutical & Pharmaceutical Companies
  • 7.2.1 Biopharmaceutical & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
• 7.3 CROs & CMOs
  • 7.3.1 CROs & CMOs market estimates and forecast, 2018 - 2030 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1 Academic & research institutes market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cloning and Mutagenesis Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

• 8.1 Cloning and Mutagenesis Market: Regional Movement Analysis
• 8.2 North America
  • 8.2.1 SWOT Analysis
    • 8.2.1.1 North America cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.2.1.2 North America cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.2.1.3 North America cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.2.1 Key Country Dynamics
    • 8.2.2.2 Target Disease Prevalence
    • 8.2.2.3 Competitive Scenario
    • 8.2.2.4 Regulatory Framework
    • 8.2.2.5 Reimbursement Scenario
    • 8.2.2.6 U.S. cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.2.2.7 U.S. cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.2.2.8 U.S. cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.2.3 Canada
    • 8.2.3.1 Key Country Dynamics
    • 8.2.3.2 Target Disease Prevalence
    • 8.2.3.3 Competitive Scenario
    • 8.2.3.4 Regulatory Framework
    • 8.2.3.5 Reimbursement Scenario
    • 8.2.3.6 Canada cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.2.3.7 Canada cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.2.3.8 Canada cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
• 8.3 Europe
  • 8.3.1 SWOT Analysis
    • 8.3.1.1 Europe cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.1.2 Europe cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.1.4 Europe cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.2 Germany
    • 8.3.2.1 Key Country Dynamics
    • 8.3.2.2 Target Disease Prevalence
    • 8.3.2.3 Competitive Scenario
    • 8.3.2.4 Regulatory Framework
    • 8.3.2.5 Reimbursement Scenario
    • 8.3.2.6 Germany cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.2.7 Germany cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.2.8 Germany cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.3 U.K.
    • 8.3.3.1 Key Country Dynamics
    • 8.3.3.2 Target Disease Prevalence
    • 8.3.3.3 Competitive Scenario
    • 8.3.3.4 Regulatory Framework
    • 8.3.3.5 Reimbursement Scenario
    • 8.3.3.6 U.K. cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.3.7 U.K. cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.3.8 U.K. cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.4 France
    • 8.3.4.1 Key Country Dynamics
    • 8.3.4.2 Target Disease Prevalence
    • 8.3.4.3 Competitive Scenario
    • 8.3.4.4 Regulatory Framework
    • 8.3.4.5 Reimbursement Scenario
    • 8.3.4.6 France cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.4.7 France cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.4.8 France cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.5 Italy
    • 8.3.5.1 Key Country Dynamics
    • 8.3.5.2 Target Disease Prevalence
    • 8.3.5.3 Competitive Scenario
    • 8.3.5.4 Regulatory Framework
    • 8.3.5.5 Reimbursement Scenario
    • 8.3.5.6 Italy cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.5.7 Italy cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.5.8 Italy cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.6 Spain
    • 8.3.6.1 Key Country Dynamics
    • 8.3.6.2 Target Disease Prevalence
    • 8.3.6.3 Competitive Scenario
    • 8.3.6.4 Regulatory Framework
    • 8.3.6.5 Reimbursement Scenario
    • 8.3.6.6 Spain cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.6.7 Spain cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.6.8 Spain cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.7 Denmark
    • 8.3.7.1 Key Country Dynamics
    • 8.3.7.2 Target Disease Prevalence
    • 8.3.7.3 Competitive Scenario
    • 8.3.7.4 Regulatory Framework
    • 8.3.7.5 Reimbursement Scenario
    • 8.3.7.6 Denmark cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.7.7 Denmark cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.7.8 Denmark cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.8 Sweden
    • 8.3.8.1 Key Country Dynamics
    • 8.3.8.2 Target Disease Prevalence
    • 8.3.8.3 Competitive Scenario
    • 8.3.8.4 Regulatory Framework
    • 8.3.8.5 Reimbursement Scenario
    • 8.3.8.6 Sweden cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.8.7 Sweden cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.8.8 Sweden cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.9 Norway
    • 8.3.9.1 Key Country Dynamics
    • 8.3.9.2 Target Disease Prevalence
    • 8.3.9.3 Competitive Scenario
    • 8.3.9.4 Regulatory Framework
    • 8.3.9.5 Reimbursement Scenario
    • 8.3.9.6 Norway cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.3.9.7 Norway cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.3.9.8 Norway cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
• 8.4 Asia Pacific
  • 8.4.1 SWOT Analysis
    • 8.4.1.1 Asia Pacific cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.1.2 Asia Pacific cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.1.3 Asia Pacific cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.2 Japan
    • 8.4.2.1 Key Country Dynamics
    • 8.4.2.2 Target Disease Prevalence
    • 8.4.2.3 Competitive Scenario
    • 8.4.2.4 Regulatory Framework
    • 8.4.2.5 Reimbursement Scenario
    • 8.4.2.6 Japan cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.2.7 Japan cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.2.8 Japan cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.3 China
    • 8.4.3.1 Key Country Dynamics
    • 8.4.3.2 Target Disease Prevalence
    • 8.4.3.3 Competitive Scenario
    • 8.4.3.4 Regulatory Framework
    • 8.4.3.5 Reimbursement Scenario
    • 8.4.3.6 China cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.3.7 China cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.3.8 China cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.4 India
    • 8.4.4.1 Key Country Dynamics
    • 8.4.4.2 Target Disease Prevalence
    • 8.4.4.3 Competitive Scenario
    • 8.4.4.4 Regulatory Framework
    • 8.4.4.5 Reimbursement Scenario
    • 8.4.4.6 India cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.4.7 India cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.4.8 India cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.5 South Korea
    • 8.4.5.1 Key Country Dynamics
    • 8.4.5.2 Target Disease Prevalence
    • 8.4.5.3 Competitive Scenario
    • 8.4.5.4 Regulatory Framework
    • 8.4.5.5 Reimbursement Scenario
    • 8.4.5.6 South Korea cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.5.7 South Korea cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.5.8 South Korea cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.6 Australia
    • 8.3.9.1 Key Country Dynamics
    • 8.4.6.2 Target Disease Prevalence
    • 8.4.6.3 Competitive Scenario
    • 8.4.6.4 Regulatory Framework
    • 8.4.6.5 Reimbursement Scenario
    • 8.4.6.6 Australia cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.6.7 Australia cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.6.8 Australia cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.7 Thailand
    • 8.4.7.1 Key Country Dynamics
    • 8.4.7.2 Target Disease Prevalence
    • 8.4.7.3 Competitive Scenario
    • 8.4.7.4 Regulatory Framework
    • 8.4.7.5 Reimbursement Scenario
    • 8.4.7.6 Thailand cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.4.7.7 Thailand cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.4.7.8 Thailand cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
• 8.5 Latin America
  • 8.5.1 SWOT Analysis
    • 8.5.1.1 Latin America cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.5.1.2 Latin America cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.5.1.3 Latin America cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Key Country Dynamics
    • 8.5.2.2 Target Disease Prevalence
    • 8.5.2.3 Competitive Scenario
    • 8.5.2.4 Regulatory Framework
    • 8.5.2.5 Reimbursement Scenario
    • 8.5.2.6 Brazil cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.5.2.7 Brazil cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.5.2.8 Brazil cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.5.3 Mexico
    • 8.5.3.1 Key Country Dynamics
    • 8.5.3.2 Target Disease Prevalence
    • 8.5.3.3 Competitive Scenario
    • 8.5.3.4 Regulatory Framework
    • 8.5.3.5 Reimbursement Scenario
    • 8.5.3.6 Mexico cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.5.3.7 Mexico cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.5.3.8 Mexico cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.5.4 Argentina
    • 8.5.4.1 Key Country Dynamics
    • 8.5.4.2 Target Disease Prevalence
    • 8.5.4.3 Competitive Scenario
    • 8.5.4.4 Regulatory Framework
    • 8.5.4.5 Reimbursement Scenario
    • 8.5.4.6 Argentina cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.5.4.7 Argentina cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.5.4.8 Argentina cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
• 8.6 MEA
  • 8.6.1 SWOT Analysis
    • 8.6.1.1 MEA cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.6.1.2 MEA cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.6.1.3 MEA cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.4.1 Key Country Dynamics
    • 8.6.2.2 Target Disease Prevalence
    • 8.6.2.3 Competitive Scenario
    • 8.6.2.4 Regulatory Framework
    • 8.6.2.5 Reimbursement Scenario
    • 8.6.2.6 Argentina cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.6.2.7 Argentina cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.6.2.8 Argentina cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.3 Saudi Arabia
    • 8.6.3.1 Key Country Dynamics
    • 8.6.3.2 Target Disease Prevalence
    • 8.6.3.3 Competitive Scenario
    • 8.6.3.4 Regulatory Framework
    • 8.6.3.5 Reimbursement Scenario
    • 8.6.3.6 Saudi Arabia cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.6.3.7 Saudi Arabia cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.6.3.8 Saudi Arabia cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.4 UAE
    • 8.6.4.1 Key Country Dynamics
    • 8.6.4.2 Target Disease Prevalence
    • 8.6.4.3 Competitive Scenario
    • 8.6.4.4 Regulatory Framework
    • 8.6.4.5 Reimbursement Scenario
    • 8.6.4.6 UAE cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.6.4.7 UAE cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.6.4.8 UAE cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.5 Kuwait
    • 8.6.5.1 Key Country Dynamics
    • 8.6.5.2 Target Disease Prevalence
    • 8.6.5.3 Competitive Scenario
    • 8.6.5.4 Regulatory Framework
    • 8.6.5.5 Reimbursement Scenario
    • 8.6.5.6 Kuwait cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
    • 8.6.5.7 Kuwait cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
    • 8.6.5.8 Kuwait cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

• 9.1 Participant's overview
  • 9.1.1 Agilent Technologies, Inc.
  • 9.1.2 Takara Bio Inc.
  • 9.1.3 Thermo Fisher Scientific, Inc.
  • 9.1.4 New England Biolabs
  • 9.1.5 Merck KGaA
  • 9.1.6 Promega Corporation
  • 9.1.7 Bio-Rad Laboratories, Inc.
  • 9.1.8 Danaher
  • 9.1.9 Jena Bioscience GmbH
  • 9.1.10 Assay Genie
  • 9.1.11 TransGen Biotech Co., Ltd.
• 9.2 Financial performance
• 9.3 Participant categorization
  • 9.3.1 Market leaders
    • 9.3.1.1 Cloning & mutagenesis market share analysis, 2022
  • 9.3.2 Strategy mapping
    • 9.3.2.1 Expansion
    • 9.3.2.2 Acquisition
    • 9.3.2.3 Collaborations
    • 9.3.2.4 Product/service launch
    • 9.3.2.5 Partnerships
    • 9.3.2.6 Others